1. Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
   Manabu Seino et al, 2018, Oncotarget CrossRef
2. Aggresome formation promotes ASK1/JNK signaling activation and stemness maintenance in ovarian cancer
   Yurou Chen et al, 2024, Nature Communications CrossRef
3. Functional Roles of JNK and p38 MAPK Signaling in Nasopharyngeal Carcinoma
   Lesley Jia Wei Pua et al, 2022, International Journal of Molecular Sciences CrossRef
4. The Jun N-terminal kinases signaling pathway plays a “seesaw” role in ovarian carcinoma: a molecular aspect
   Yingyu Dou et al, 2019, Journal of Ovarian Research CrossRef
5. Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives
   Chunqiu Yu et al, 2020, Journal of Medicinal Chemistry CrossRef
6. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
   Yi‐Nan Liu et al, 2019, International Journal of Cancer CrossRef
7. Circular RNA circ_0004488 Increases Cervical Cancer Paclitaxel Resistance via the miR-136/MEX3C Signaling Pathway
   Hanjie Yi et al, 2022, Journal of Oncology CrossRef
8. Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15
   Hirotaka Nishi et al, 2023, Gynecologic Oncology Reports CrossRef
9. The role of endolysosomal trafficking in anticancer drug resistance
   Noor A. Hussein et al, 2021, Drug Resistance Updates CrossRef
10. Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies
    Kathleen Wantoch von Rekowski et al, 2020, International Journal of Molecular Sciences CrossRef
11. Exploiting Nanocarriers for Combination Cancer Therapy
    Yi Wen Kong et al, 2016, Intracellular Delivery III CrossRef
12. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer
    Ji Hee Ha et al, 2016, Oncotarget CrossRef
13. Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy
    Zilan Zhou et al, 2017, Molecular Pharmaceutics CrossRef
14. Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
    Shannon Lee et al, 2020, International Journal of Molecular Sciences CrossRef
15. Inhibition of c-Jun N-terminal kinase signaling promotes osteoblastic differentiation of periodontal ligament stem cells and induces regeneration of periodontal tissues
    Hiroshi Kaneko et al, 2022, Archives of Oral Biology CrossRef
16. xCT inhibitor sulfasalazine depletes paclitaxel‑resistant tumor cells through ferroptosis in uterine serous carcinoma
    Akiko Sugiyama et al, 2020, Oncology Letters CrossRef
17. Antitumor activity of gemcitabine against high-grade meningiomain vitroandin vivo
    Hiroyuki Takeda et al, 2017, Oncotarget CrossRef